Neovasc Inc.

13700 Mayfield Place
Suite 2135
Richmond
British Columbia
V6V 2E4
Canada

Tel: 604-270-4344
Fax: 604-270-4384

Email: info@neovasc.com

Show jobs for this employer

302 articles with Neovasc Inc.

  • Neovasc, Inc. (NASDAQ, TSX: NVCN) today announced that it will report financial results for the quarter ended September 30, 2020 after the market close on November 5, 2020.

  • Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that it will sponsor a symposium entitled “Unmet Need in Treating Patients With Refractory Angina” at the 2020 TCT Connect Online Conference, taking place October 14-18, 2020.

  • Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, today announced that its management team will be participating in the 22nd Annual H.C. Wainwright Global Investment Conference on September 14-16, 2020. 

  • Neovasc Inc. is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on September 3, 2020 in Vancouver, B.C..

  • Neovasc Inc. announced that Strul Medical Group LLC exercised 501,000 of the remaining 1,149,910 common share purchase warrants issued pursuant to a Securities Purchase Agreement dated May 26, 2020 at an exercise price of US$2.634 per May Warrant for aggregate exercise proceeds to the Company of US$1,319,634.00.

  • Neovasc, Inc., provided a corporate update on progress towards its value creation strategies.

  • Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN / TSX: NVCN) announced today that it has closed its previously announced registered direct offering (the “Offering”) priced at-the-market under the Nasdaq rules of an aggregate of 4,532,772 common shares at a purchase price of US$2.77575 per common share for aggregate gross proceeds to the Company of approximately US$12.6 million

  • Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN / TSX: NVCN) announced today that it has entered into definitive agreements with certain healthcare-focused institutional investors for the sale of an aggregate of 4,532,772 common shares at a purchase price of US$2.77575 per common share in a registered direct offering (the “Offering”) priced at-the-market under the Nasdaq Capital Market (the "Nasdaq") rules for ag

  • Neovasc, Inc., a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, reported financial results for the second quarter ended June 30, 2020.

  • Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) announced today that the Neovasc Reducer™ (the “Reducer”) was featured in a supplement titled: “Volkskrankheiten” or “Common Diseases” in Frankfurter Allgemeine Zeitung(FAZ),

  • Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) announced today that Strul Medical Group LLC (“SMG”) exercised 1,424,049 of the 2,573,959 common share purchase warrants (the “May Warrants”) issued pursuant to a Securities Purchase Agreement dated May 26, 2020 at an exercise price of US$2.634 per May Warrant

  • Neovasc, Inc.  ("Neovasc" or the "Company") ( NASDAQ ,  TSX : NVCN), announced today that it has been informed by the U.S. Food and Drug Administration (FDA) that the Circulatory System Devices Panel of the Medical Devices Advisory Committee will review the premarket approval application (PMA) for the Neovasc Reducer™ device (“Reducer”) at its October 27, 2020 meeting. Neovasc is seeking approval for Reducer in t

  • Neovasc, Inc.  ( NASDAQ ,  TSX : NVCN) today announced preliminary revenue results for the second quarter of 2020. Revenue for the quarter ended June 30, 2020 was approximately $295,000. Revenues were negatively impacted by a reduction in Reducer procedures that began in mid-March and persisted through early June. Despite a marked slowdown in the num

  • Neovasc Inc.  ("Neovasc" or the "Company") ( NASDAQ ,  TSX : NVCN), today announced positive interim results of the REDUCER-I study during the PCR E-Course. Stefan Verheye, MD, PhD, ZNA Middelheim, Antwerp, Belgium presented the results of the trial during the Hotline and Innovation Session. REDUCER-I is a multi-center, international, three-arm prospective and retrospective observational study enrolling up to 4

  • Neovasc Inc.  ("Neovasc" or the "Company") ( NASDAQ ,  TSX : NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, announced today that it has closed its previously announced registered direct offering (the “Offering”) priced at-the-market under Nasdaq rules of an aggregate of 3,883,0

  • Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN / TSX: NVCN) announced today that it has entered into definitive agreements with certain healthcare-focused institutional investors for the sale of an aggregate of 3,883,036 common shares at a purchase price of US$2.97375 per common share in a registered direct offering (the “Offering”) priced at-the-market under Nasdaq rules for aggregate gross proceeds to the Company of

  • Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, announced today that the Neovasc Reducer™ (“Reducer”) and Tiara™ (“Tiara”) program will be featured at two industry conferences this month.

  • Neovasc Inc.  ("Neovasc" or the "Company") ( NASDAQ ,  TSX : NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, announced today that, further to its press release dated May 26, 2020, the Company has issued a final convertible note in the principal amount US$1 million to Strul

  • Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, today announced that the Neovasc Reducer™ device

  • Company outlines milestone achievements towards value creation